This review summarises the progress made in cutting through the biological and genetic complexity of the Gordian-knot that is Familial Combined Hyperlipidemia.
Introduction
This review considers the potential power of new and emerging genomic technologies to solve a clinically important yet seemingly intractable problem, the genetic dissection and consequent biological understanding of Familial Combined Hyperlipidemia (FCHL). The reason for this focus is three-fold. First, the genetic complexity of this condition is undoubtedly rooted in the diversity of the intra-and inter-cellular processes of the various organs that govern serum cholesterol and triglyceride levels (1) (2) (3) (4) . As such, only the application of the new generation of genomic tools, in particular massively parallel sequencing (Mps) (5) (6) (7) (8) and microarray technologies (9) (10) (11) , has the capability to comprehensively identify and characterise the genomic variants that contribute to the transmission and manifestation of this common, highly atherogenic disorder (12, 13) . Secondly, the wealth of data emerging from the application of these tools will provide important genetic information to supplement the traditional family-based, biochemical diagnosis of FCHL, thereby promising to resolve the current controversy over diagnostic criteria (14) (15) (16) (17) , as well as offering the prospect of early therapeutic intervention. Thirdly, comparative analysis of the data from multiple human genomes, obtained with the new tools, will enormously expand knowledge (and perhaps even our understanding) of the contribution that lipids make to a diverse range of cellular activities from conception 4 Current data suggest that both common and rare variants underlie FCHL, with the specific contributions of each form varying from cohort to cohort, family to family, and even from family member to family member (15, (24) (25) (26) . In short, the mixed patterns of hyperlipidemia in FCHL families may result from either specific combinations of common variants (Figure) , with each allele having only a small influence on serum lipid values (common-disease-common-variant hypothesis); or multiple, rare, functionally deleterious variants each individually affecting a handful of pedigrees (common-disease-multiple-rare-variant hypothesis), or a combination of both.
Characterising the Lipid Exome
The per-unit-cost and high-throughput of the new genomic technologies now offer the possibility of sequencing the entire lipid exome (operationally defined as exons of all known 'lipid metabolism' genes and liberally extended to include those regulating their pre-and post-transcriptional events) of FCHL patients. In fact three recent studies provide the impetus to do so. In the first, Venter and colleagues (27) showed that the genome of a healthy individual contained ~10,400 nonsynonymous protein coding variants, of which ~1,100 are predicted to affect function. These variants were predominantly heterozygous (n=801), with a sizeable proportion being rare (n=79) or novel (n=101) in the human population according to genomic databases. In the next study, Kryukov et al (28) used data from the Human Gene Mutation Database (containing 50,000+ disease-causing mutations), four large sequencing projects and human-chimpanzee sequence divergence patterns to assess whether the commondisease-multiple-rare-variant hypothesis is viable. They found that ~53% of the observed missense mutations had reached detectable frequencies in the human by guest, on www.jlr.org Downloaded from 5 population (i.e. >1/1500 chromosomes) despite being deleterious, and argued that their prevalence and highly heterogeneous nature was attributable to relatively weak selection pressure being applied to the individual variants. Their calculations also revealed that an average protein of 500 amino acids contains a deleterious missense mutation in ~1% of the human population, implying that a hypothetical set of 50 proteins, defined by their contribution to a common biological network, could easily contain such a mutation in one or more members of this protein set, in a sizeable proportion of the population. They therefore concluded that multiple rare variants could make appreciable contributions to the aetiologies of common, genetically complex diseases. In the third study, Ahituv et al (29) Moreover, it was discerned that a higher proportion of those variants in the obese group were likely to be functionally deleterious than in the lean group (19 versus (vs) 4; P<0.002). By contrast, the number of functionally 'deleterious' variants in the group B 'control' genes did not differ significantly between obese and lean individuals (21 vs 27) . In summary, the data from these three studies suggest that a highly heterogeneous spectrum of nonsynonymous coding variants are likely to lurk in the genomes of FCHL patients, with a high proportion of the functionally deleterious changes residing in their lipid exomes.
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To assess the common-disease-multiple-rare-variant hypothesis for the dyslipidemias, several investigators have already applied 'yesterday's technologies', yielding some tantalizing results. For example, Wang et al (30) showed that a LPL or APOC2
coding mutation was present on one allele in 10% of hypertriglyceridemic patients, while Cohen et al (31) demonstrated that nonsynonymous changes in ABCA1, APOA1
and LCAT were more common (16% vs 2%) in people with low HDL-C levels (<5 th age-sex percentile (asp)) than in those with high HDL-C (>95 th asp). Additionally, Civeira et al (32) found that 19.6% of their 143 Spanish FCHL patients had a LDLR mutation, and understandably argued that these individuals might be more accurately diagnosed as having the FCHL phenotype rather than the disease per se. In detail, using microarray chips containing 203 detrimental LDLR variants, they established that 23 of their patients had a mutation on one allele, while five bore two such variants (presumably on the same allele). Moreover, as would be anticipated, they
showed that the patient group bearing a LDLR mutation (22 different variants) had higher mean total cholesterol, LDL-C and apoB levels, plus smaller waist circumferences than those who did not. Disappointingly, Civeira et al (32) did not examine whether the mutations segregated with hypercholesterolemia in their 'FCHL' families, which would have provided more information on the potential overlap between 'monogenic' Familial Hypercholesterolemia and the more complex disorder, FCHL. In a similar study, Cianflone and colleagues (26) Turning to the common-disease-common-variant hypothesis, there is compelling evidence that relatively common variants in the ApoA1/C3/A4/A5 complex contribute to FCHL (15, 33) although, as discussed in two excellent reviews (34, 35) , the exact mechanisms by which these single nucleotide polymorphisms (SNPs) alter serum lipid levels are not fully resolved. By sequencing the retinoid X receptor γ (RXRγ) gene in 180 hyperlipidemic patients, Nohara et al (36) found the common variant Gly14Ser. They showed it was more prevalent in FCHL probands (9/60; 15%) compared to peers with other forms of hyperlipidemia (5/120; 4%) and the general Japanese population (15/298; 5%). Rather unexpectedly they did not find the RXRγ Ser14 variant to be more prevalent in patients (age 58+7years) suspected of having coronary heart disease (9/175; 5% After SNPs, insertion/deletions (indels) are the most common type of genetic variation in the human exome (27) , and indeed we have known for some time that common indels within the lipid exome (e.g. apoB, LPL) quantitatively influence serum lipid levels (37, 38) . Less clear is whether there are rare indels making more substantial contributions to dyslipidemia and it is this question that Mps, combined with high-throughput genotyping methodologies, can readily address. In this respect, the rare PCSK9 indel, designated p.L15_L16ins2L (39) Recent technical and statistical advances (41) (42) (43) (44) indicate that it is now timely to examine the copy number variant/polymorphism content of FCHL-patients' lipid exome. The rationale being that copy number variants contribute to autism (45) and neurodevelopmental pathways in schizophrenia (46) . Additionally, psoriasis is associated with increased β-defensin genomic copy number (47) .
Revisiting FCHL Linkage Intervals
As spelt out by Kahvejian et al (5) , the new sequencing technologies have yet to reach the nucleotide unit-cost that would permit submission of a grant application to sequence the entire genome of, say, 200 FCHL patients and controls without automatically being filed under fantasy. Thus, for now, much high-density sequencedriven FCHL research will necessarily be confined to analysing those genomic intervals (lipid exomic or otherwise) linked to its component traits (15, 48) this study nicely demonstrates the efficacy of a SNP-based approach to detect modifier variants that have risen to high-frequencies in the human population, presumably because they were not evolutionarily disadvantageous. It also highlights that a more in-depth analysis of the WWOX locus is warranted; specifically, to establish whether the rs2548861 T allele is merely acting as a marker for a rarer functional variant(s) that has a more substantial impact on an individual's HDL-C than current estimates; and additionally to identify whether rare variants at the WWOX locus are enriched in patient groups with low-HDL-C levels.
Many investigators (15) Table) . At susceptibility loci, the 181-family datasets (300 simulations) generated mean LOD scores ~2-fold higher than those observed in the 60-family datasets. LOD scores were also generally higher in the chromosomal regions allocated two susceptibility variants (e.g. chromosome 1) and in the single region carrying three variants (chromosome 11), LOD scores were higher still. This 'heterogeneous' region was the only one to consistently return values exceeding the classical thresholds (50) for declaring linkage.
We present the results from the simulations performed on real family structures to make a fundamental point: genuine FCHL susceptibility variants will exist in some of the chromosomal regions that have returned LOD scores just missing threshold levels for declaration of linkage (50) , simply because obtaining significant/confirmed LOD scores is difficult in the face of genetic heterogeneity, genomic imprinting, heterogeneity across cohorts and the multiple other factors highlighted by Pollex and Hegele (48) . Thus, although there is a clear need to develop new statistical methods to overcome these obstacles, we suggest that the process of cutting through the Gordian-knot of biological and genetic complexity that is FCHL can now be accelerated by incorporating the wealth of information emerging from the application of the new genomic and proteomic technologies (5) (6) (7) (9) (10) (11) with both existing and improved linkage data. Hypothetical mode of transmission of the FCHL-cholesterol (TC), triglyceride (TG) and combined hyperlipidemia (CHL) traits. Family was ascertained through a white British proband (indicated by arrow) with serum TC>95 th and TG>90 th age-sexspecific percentiles. Exclusion criteria were as described (15). Colour-coding of variants: TC, red shades; TG, blue; CHL, purple. Phenotypic effect of variants proportional to tile size, frequency is inversely proportional. 
